149022-18-4 Usage
Uses
Used in Pharmaceutical Research:
D,L-THREO-1-PHENYL-2-HEXADECANOYLAMINO-3-MORPHOLINO-1-PROPANOL HCL is used as a research compound for studying the role of glucosylceramide synthase in cell growth and apoptosis. Its inhibition of glucosylceramide synthase can provide insights into the underlying mechanisms of cellular processes and contribute to the development of novel therapeutic strategies for various diseases.
Used in Cell Biology:
In the field of cell biology, D,L-THREO-1-PHENYL-2-HEXADECANOYLAMINO-3-MORPHOLINO-1-PROPANOL HCL is used as a tool to investigate the functions and regulation of glucosylceramide synthase. This can help researchers understand the complex interactions between cellular components and the role of ceramide metabolism in cellular signaling and homeostasis.
Used in Drug Development:
D,L-THREO-1-PHENYL-2-HEXADECANOYLAMINO-3-MORPHOLINO-1-PROPANOL HCL is used as a lead compound in the development of new drugs targeting glucosylceramide synthase. Its ability to inhibit this enzyme may lead to the creation of novel therapeutic agents for the treatment of diseases associated with dysregulated ceramide metabolism, such as cancer and neurodegenerative disorders.
Check Digit Verification of cas no
The CAS Registry Mumber 149022-18-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,9,0,2 and 2 respectively; the second part has 2 digits, 1 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 149022-18:
(8*1)+(7*4)+(6*9)+(5*0)+(4*2)+(3*2)+(2*1)+(1*8)=114
114 % 10 = 4
So 149022-18-4 is a valid CAS Registry Number.
InChI:InChI=1/C29H50N2O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-17-20-28(32)30-27(25-31-21-23-34-24-22-31)29(33)26-18-15-14-16-19-26/h14-16,18-19,27,29,33H,2-13,17,20-25H2,1H3,(H,30,32)/t27-,29-/m1/s1
149022-18-4Relevant academic research and scientific papers
Methods for treating conditions modulated by lactosylceramide
-
, (2008/06/13)
The present invention includes methods for treatment and prophylaxis of conditions associated with lactosylceramide. The methods generally provide for administration to a mammal, particularly a human, of a therapeutically effective amount of a compound that increases enzymatic activity of UDPGal:GlcCerβ1→4 galactosylceramide (GalT-2). In vitro and in vivo assays for detecting compounds with therapeutic capacity to modulate GalT-2 are also provided.
Methods for treatment of conditions associated with lactosylceramide
-
, (2008/06/13)
The present invention includes methods for treatment and prophylaxis of diseases, post-surgical disorders and bacterial infections associated with lactosylceramide. The methods generally provide for administration for a mammal, particularly a human, of a therapeutically effective amount of a compound that inhibits UDPGal:GlcCerβ1->4 galactosylceramide (GalT-2). In vitro and in vivo assays for detecting compounds with therapeutic capacity to modulate GalT-2 are also provided.
